Eli Lilly and Co (LSE:LEL)
$ 56.25 0 (1.24%) Market Cap: 63.81 Bil Enterprise Value: 91.49 Bil PE Ratio: 87.15 PB Ratio: 50.94 GF Score: 87/100

Eli Lilly and Co at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 04:20PM GMT
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Going with our next company presenter. My name is Jason Gerberry. I'm the U.S. Pharma Analyst at Bank of America. I'm pleased to be introducing Eli Lilly and Enrique Conterno. Enrique runs Lilly's Diabetes Division. So very topical, as diabetes is an important growth driver for the company. Trulicity is very topical coming out of the quarter.

So thank you, Enrique, for joining us.

Enrique A. Conterno
Eli Lilly and Company - Senior VP & President of Lilly Diabetes and Lilly USA

Very good. No, pleasure to be here.

Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

So maybe we can just start the discussion with your Trulicity franchise. It's obviously been one of the important growth drivers for the company, and really an impressive volume growth story for Lilly.

Can you talk about -- we've seen a very massive inflection in market share, I feel like, in the last 12 to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot